BirchBioMed reports breakthrough phase 2 trial results for FS2 in treating keloid scars

BirchBioMed, a Canadian clinical-stage immunology company, has unveiled promising results from a phase 2 trial of FS2, its pioneering antifibrotic therapy designed to treat keloid ... Read More